Cempra Inc. (NASDAQ:CEMP) has received a consensus rating of “Buy” from the thirteen ratings firms that are covering the company. Three investment analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $38.44.

Several equities research analysts have issued reports on CEMP shares. Cowen and Company reiterated a “buy” rating on shares of Cempra in a research note on Friday, June 24th. Stifel Nicolaus decreased their price objective on shares of Cempra from $51.00 to $47.00 and set a “buy” rating for the company in a research note on Friday, June 24th. Zacks Investment Research cut shares of Cempra from a “buy” rating to a “hold” rating in a research report on Thursday, August 11th. Jefferies Group reduced their target price on shares of Cempra from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, August 2nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $48.00 target price on shares of Cempra in a research report on Friday, June 24th.

Cempra (NASDAQ:CEMP) opened at 22.45 on Thursday. The stock’s market capitalization is $1.17 billion. Cempra has a 12 month low of $14.03 and a 12 month high of $34.24. The firm’s 50-day moving average is $23.22 and its 200 day moving average is $19.51.

Cempra (NASDAQ:CEMP) last released its quarterly earnings data on Monday, August 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.16. Cempra had a negative net margin of 715.34% and a negative return on equity of 63.54%. The company earned $3.42 million during the quarter, compared to the consensus estimate of $3.89 million. During the same period in the previous year, the firm earned ($0.57) earnings per share. Cempra’s revenue for the quarter was down 33.3% on a year-over-year basis. On average, equities analysts anticipate that Cempra will post ($2.63) earnings per share for the current year.

Several hedge funds have recently modified their holdings of the company. Legal & General Group Plc boosted its stake in shares of Cempra by 23.0% in the first quarter. Legal & General Group Plc now owns 6,711 shares of the company’s stock worth $114,000 after buying an additional 1,256 shares during the period. Quantitative Investment Management LLC boosted its stake in shares of Cempra by 3.8% in the second quarter. Quantitative Investment Management LLC now owns 16,300 shares of the company’s stock worth $268,000 after buying an additional 600 shares during the period. UBS Asset Management Americas Inc. boosted its stake in shares of Cempra by 22.9% in the second quarter. UBS Asset Management Americas Inc. now owns 17,700 shares of the company’s stock worth $292,000 after buying an additional 3,300 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in shares of Cempra by 7.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 17,953 shares of the company’s stock worth $296,000 after buying an additional 1,199 shares during the period. Finally, Johnson Investment Counsel Inc. boosted its stake in shares of Cempra by 1.0% in the second quarter. Johnson Investment Counsel Inc. now owns 19,590 shares of the company’s stock worth $323,000 after buying an additional 200 shares during the period. 78.31% of the stock is currently owned by institutional investors.

Cempra Company Profile

Cempra, Inc is a clinical-stage pharmaceutical company. The Company is focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections.

5 Day Chart for NASDAQ:CEMP

Receive News & Stock Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related stocks with our FREE daily email newsletter.